Butyrylcholinesterase in the life cycle of amyloid plaques

Annals of Neurology

Volumn 42, Issue 6, 1997, Pages 909-918

  Guillozet, A L ^a,c   Smiley, J F ^a   Mash, D C ^b   Mesulam, M M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINESTERASE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONFORMATIONAL TRANSITION; CYTOARCHITECTURE; FEMALE; HUMAN; HUMAN TISSUE; MALE; NERVE CELL DEGENERATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DETERMINATION; SENILE PLAQUE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BUTYRYLCHOLINESTERASE; CASE-CONTROL STUDIES; FEMALE; FLUORESCENT DYES; HUMANS; MALE; MIDDLE AGED; SENILE PLAQUES; TEMPORAL LOBE; THIAZOLES;

EID: 0031458235     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420613     Document Type: Article

References (80)

1. Mirra S, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486
2. Khachaturian Z. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105
3. Mann D, Brown A, Prinja D, et al. An analysis of the morphology of senile plaques in Down's syndrome patients of different ages using immunocytochemical and lectin histochemical techniques. Neuropathol Appl Neurobiol 1989;15:317-329
4. Schellenberg G, Bird T, Wijsman E, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992;258:668-671
5. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992;1:345-347
6. Chartier-Harlin M-C, Crawford F, Houlden H, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 1991;353:844-846
7. Karlinsky H, Vaula G, Haines J, et al. Molecular and prospective phenotypic characterization of a pedigree with familial Alzheimer's disease and a missense mutation in codon 717 of the β-amyloid precursor protein gene. Neurology 1992;42:1445-1453
8. Fidani L, Rooke K, Chartier-Harlin M-C, et al. Screening for the mutations in the open reading frame and promoter of the β-amyloid precursor protein gene in familial Alzheimer's disease: identification of a further family with APP717 Val-→Ile. Hum Mol Genet 1992;1:165-168
9. Suzuki N, Cheung T, Cai X, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta-APP 717) mutant. Science 1994;264: 1336-1340
10. 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 1996;148:1257-1266
11. Refolo L, Harigaya Y, Younkin L, et al. Analysis of presenilin 1 in brain and cultured cells. Soc Neurosci Abstr 1996;22:278 (Abstract)
12. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870
13. Mann D, Iwatsubo T, Nochlin D, et al. Amyloid (Aβ) deposition in chromosome 1-linked Alzheimer's disease: the Volga German families. Ann Neurol 1997;41:52-57
14. 42(43). Ann Neurol 1996;40:149-156
15. Mann D, Esiri M. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 1989;89:169-179
16. Giannakopoulos P, Hof P, Giannakopoulos A-S, et al. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of very old patients. Arch Neurol 1995;52: 1150-1160
17. Mackenzie I. Senile plaques do not progressively accumulate with normal aging. Acta Neuropathol 1994;87:520-525
18. Guillozet A, Smiley J, Mash D, Mesulam M. The amyloid burden of the cerebral cortex in non-demented old age. Soc Neurosci Abstr 1995;21:1478 (Abstract)
19. Arriagada P, Growdon J, Hedley-Whyte E, Hyman B. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639
20. Cummings B, Pike C, Shankle R, Cotman C. β-Amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 1996;17:921-933
21. Ikeda S-I, Yanagisawa N, Allsop D, Glenner G. Evidence of amyloid β-protein immunoreactive early plaque lesions in Down's syndrome brains. Lab Invest 1989;61:133-137
22. Wilcock G, Esiri M. Plaques, tangles and dementia. J Neurol Sci 1982;56:343-356
23. Delaère P, Duychaerts C, Brion J, et al. Tau, paired helical filaments and amyloid in the neocortex: a morphometric study of 15 cases with graded intellectual status in aging and senile dementia of Alzheimer type. Acta Neuropathol 1989;77:645-653
24. Nagy Z, Esiri M, Jobst K, et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 1995;6: 21-31
25. Citron M, Diehl T, Sherrington R, et al. Stable expression of mutant presenilins has differential effects on Aβ42 and Aβ40 production. Soc Neurosci Abstr 1996;22:278 (Abstract)
26. 42 production in stably transfected CHO cells. Soc Neurosci Abstr 1996;22:278 (Abstract)
27. Iwatsubo T, Mann D, Tomita T, et al. Effects of presenilin mutations on the deposition and production of amyloid β protein. Soc Neurosci Abstr 1996;22:278 (Abstract)
28. Snyder S, Ladror U, Wade W, et al. Amyloid-β aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 1994;67:1216-1228
29. Hilbich C, Kisters-Woike B, Reed J, et al. Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J Mol Biol 1991;218:149-163
30. Burdick D, Soreghan B, Kwon M, et al. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J Biol Chem 1992;267:546-554
31. Pike C, Burdick D, Wlaencewicz A, et al. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993;13:1676-1687
32. Fukumoto H, Asami-Odaka A, Suzuki N, et al. Amyloid β protein deposition in normal aging has the same characteristics as that in Alzheimer's disease: predominance of Aβ42(43) and association of Aβ40 with cored plaques. Am J Pathol 1996;148: 259-265
33. Iwatsubo T, Mann D, Odaka A, et al. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann Neurol 1995;37:294-299
34. Jarrett J, Berger E, Lansbury PJ. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32:4693-4697
35. Abraham C, Selkoe D, Potter H. Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988;52: 487-501
36. Rozemuller J, Eikelenboom P, Stam F, et al. A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol 1989; 48:674-691
37. Snow A, Sekiguchi R, Nochlin D, et al. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am J Pathol 1994;144: 337-347
38. Kalaria R, Perry G. Amyloid P component and other acute-phase proteins associated with cerebellar Aβ-deposits in Alzheimer's disease. Brain Res 1993;631:151-155
39. Duong T, Pommier E, Scheibel A. Immunodetection of the amyloid P component in Alzheimer's disease. Acta Neuropathol 1989;78:429-437
40. Rosenblatt D, Geula C, Mesulam M-M. Protease nexin I immunostaining in Alzheimer's disease. Ann Neurol 1989;26: 628-634
41. Eikelenboom P, Stam F. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Virchows Arch [B] 1984;47:17-25
42. Eikelenboom P, Hack C, Rozemuller J, Stam F. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch [B] 1989;56:259-262
43. Kalaria R, Kroon S. Complement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer's disease. Biochem Biophys Res Commun 1992;186:461-466
44. McGeer P, Akiyama H, Itagaki S, McGeer E. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989;107:341-346
45. McGeer P, Akiyama H, Itagaki S, McGeer E. Immune system response in Alzheimer's disease. Can J Neurol Sci 1989;16: 516-527
46. Rogers J, Cooper N, Webster S, et al. Complement activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 1992;89:10016-10020
47. Rozemuller J, Stam F, Eikelenboom P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci Lett 1990;119:75-78
48. Namba Y, Tomonaga M, Kawasaki H, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991;541:163-166
49. Strittmatter W, Saunders A, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981
50. Ma J, Yee A, Brewer B Jr, et al. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994;372:92-94
51. Choi-Miura N-H, Ihara Y, Fukuchi K, et al. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol 1992;83: 260-264
52. McGeer P, Kawamata T, Walker D. Distribution of clustering in Alzheimer brain tissue. Brain Res 1992;579:337-341
53. Friede R. Enzyme histochemical studies of senile plaques. J Neuropathol Exp Neurol 1965;24:477-491
54. Morán M, Mufson E, Gomez-Ramos P. Colocalization of cholinesterases with β-amyloid protein in aged and Alzheimer's brains. Acta Neuropathol 1993;85:362-369
55. Wright C, Geula C, Mesulam M. Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993;34:373-384
56. Morris J, Heyman A, Mohs R, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-1165
57. Welsh K, Butters N, Mohs R, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994;44:609-614
58. Tago H, Kimura H, Maeda T. Visualization of detailed acetylcholinesrerase fiber and neuron staining in rat brain by a sensitive histochemical procedure. J Histochem Cytochem 1986; 34:1431-1438
59. Joachim C, Mori H, Selkoe D. Amyloid β-protein deposition in tissues other than brain in Alzheimer's disease. Nature 1989; 341:226-230
60. Tamaoka A, Kalaria R, Lieberburg I, Selkoe D. Identification of a stable fragment of the Alzheimer amyloid precursor containing the beta-protein in brain microvessels. Proc Natl Acad Sci USA 1992;89:1345-1349
61. Haas C, Schlossmacher M, Hung A, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322-325
62. 28k within the cholinergic neurons of the basal forebrain, striatum and hrainstem in the rat, monkey, baboon and human. Neuroscience 1993;54:461-476
63. Simmons L, Kay P, Tomaselli K, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 1994;45:373-379
64. Mesulam M, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-727
65. Perry E, Perry R, Blessed G, Tomlinson B. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273-277
66. Mesulam M, Moran M. Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Ann Neurol 1987;22:223-228
67. Coleman A, Geula C, Price B, Mesulam M. Differential laminar distribution of acetylcholinesterase and butyrylcholinesterase containing tangles in the cerebral cortex of Alzheimer's disease. Brain Res 1992;596:340-344
68. Mesulam M, Carson K, Price B, Geula C. Cholinesterases in the amyloid angiopathy of Alzheimer's disease. Ann Neurol 1992;31:565-569
69. Barber K, Mesulam M, Kraft G, Klein W. Butyrylcholinesterase (BChE) alters the aggregation state of Aβ amyloid. Soc Neurosci Abstr 1996;22:1172 (Abstract)
70. 1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp Neurol 1995;136:22-31
71. Soreq H, Lapidot-Lifson Y, Zakut H. A role for cholinesterases in tumorigenesis. Cancer Cells 1991;3:511-516
72. Layer P, Alber R, Rathjen F. Sequential activation of butyrylcholinesterase in rostral half somites and acetylcholinesterase in motoneurones and myotomes preceding growth of motor axons. Development 1988;102:387-396
73. Layer P, Weikert T, Alber R. Cholinesterases regulate neurite growth of chick nerve cells in vitro by means of non-enzymatic mechanism. Cell Tissue Res 1993;273:219-226
74. Jones S, Holmes C, Budd T, Greenfield S. The effect of acetylcholinesterase on outgrowth of dopaminergic neurons in organotypic slice culture of rat mid-brain. Cell Tissue Res 1995; 279:323-330
75. Boopathy A, Balasubramanian A. Peptidase activity exhibited by human serum pseudocholinesterase. Eur J Biochem 1987; 162:191-197
76. Rao R, Balasubramanian A. Localization of the peptidase activity of human serum butyrylcholinesterase in a ∼50-kDa fragment obtained by limited α-chymotrypsin digestion. Eur J Biochem 1990;188:637-643
77. Wright C, Geula C, Mesulam M. Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:683-686
78. McGeer P, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990;335:1037 (Abstract)
79. Ehrlich G, Ginzberg D, Loewenstein Y, et al. Population diversity and distinct haplotype frequencies associated with AChE and BChE genes of Israeli Jews from trans-Caucasian Georgia and from Europe. Genomics 1994;22:288-295
80. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997;6:1933-1936